# Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

> **NCT04024891** · PHASE2 · COMPLETED · sponsor: **Ocuphire Pharma, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Mydriasis
- Dilation

## Interventions

- **DRUG:** Phentolamine Mesylate Ophthalmic Solution 1%
- **OTHER:** Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)

## Key facts

- **NCT ID:** NCT04024891
- **Lead sponsor:** Ocuphire Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-13
- **Primary completion:** 2019-09-17
- **Final completion:** 2019-09-17
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024891, "Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04024891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*